Alpelisib (PIQRAY) is a targeted therapy for patients with breast-related diseases with specific gene mutations. Its unique mechanism of action brings new hope for treatment for patients with breast-related diseases.

What are the precautions for Alpelisib (PIQRAY)?

According to the drug instructions, the precautions for Alpelisib mainly include the following points. Patients should pay close attention to their own reactions during medication. If they feel uncomfortable, they should seek medical attention in time.

Severe allergic reactions

Alpelisib may cause severe allergic reactions, including anaphylactic shock. Patients should be aware of the signs and symptoms of allergic reactions, such as difficulty breathing, flushing, rash, fever or tachycardia. Once these symptoms occur, they should seek medical attention immediately and consider permanently discontinuing Alpelisib.

Severe skin adverse reactions (scar)

During the treatment with Alpelisib, patients should be alert to possible severe skin adverse reactions, such as Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN) and DRESS syndrome. Once relevant symptoms occur, treatment should be interrupted immediately and evaluated. If a severe skin adverse reaction is confirmed, Alpelisib should be permanently discontinued; if not confirmed, the treatment regimen may need to be adjusted according to the condition.

Hyperglycemia

Alpelisib may cause hyperglycemia and even hyperglycemic hyperosmolar non-ketotic syndrome (HHNKS) or ketoacidosis. Before and during treatment, patients should monitor blood sugar levels regularly and adjust according to clinical indications. Patients with risk factors for hyperglycemia, such as obesity, history of hyperglycemia, etc., should monitor blood sugar more frequently and consider strengthening hyperglycemia treatment.

Pneumonia

The use of Alpelisib may cause severe pneumonia and interstitial lung disease. Patients should pay close attention to respiratory symptoms such as cough and dyspnea. If these symptoms occur, seek medical attention immediately for evaluation. Patients diagnosed with pneumonia should permanently discontinue Alpelisib.

Diarrhea or colitis

Alpelisib may cause diarrhea or colitis, which may lead to dehydration and acute kidney injury in severe cases. Patients should pay close attention to diarrhea symptoms and adjust treatment regimens according to their condition. If diarrhea or other symptoms of colitis occur, such as abdominal pain, mucus or blood in the stool, you should seek medical attention immediately for evaluation and treatment.

Embryo-fetal toxicity

Alpelisib may have toxic effects on the embryo and fetus. During treatment with Alpelisib and within 1 week after the last dose, women of childbearing potential should take effective contraceptive measures.

Warm reminder: During treatment with Alpelisib, patients should pay close attention to their physical condition, especially the several adverse reactions mentioned above. Maintain good communication with medical staff and promptly feedback any problems during treatment.